⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15866369 | 0.83 | KDM4E (0.33) | — | |
| SCHEMBL14926276 | 0.75 | GRM5 (0.32) | — | |
| SCHEMBL798461 | 0.72 | GRM5 (0.33) | — | |
| SCHEMBL14925541 | 0.70 | GRM5 (0.35) | — | |
| SCHEMBL12128965 | 0.67 | PDK1 (0.48) | — | |
| SCHEMBL2664923 | 0.67 | PDK1 (0.48) | — | |
| SCHEMBL14925538 | 0.66 | — | — | |
| SCHEMBL21395320 | 0.66 | APOBEC3A (0.52) | — | |
| SCHEMBL18237751 | 0.63 | — | — | |
| SCHEMBL24805722 | 0.62 | GRM5 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CAPELLA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11242352-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210061816-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200291007-A1 | BENZIMIDAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CAPELLA THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-10683304-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10647707-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10590108-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CAPELLA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190169204-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |